IR@PKUHSC  > 北京大学第二临床医学院  > 血液科
学科主题临床医学
A pilot study of low-dose recombinant interleukin-2 for acute lymphoblastic malignancy after unmanipulated allogeneic blood and marrow transplantation
Liu, K-Y; Chen, Y-H; Liu, D-H; Xu, L-P; Huang, X-J
关键词Interleukin-2 Acute Lymphoblastic Malignancy Hematopoietic Stem Cell Transplantation Allogeneic Non-t-cell-depleted
刊名BONE MARROW TRANSPLANTATION
2008-10-01
DOI10.1038/bmt.2008.208
42期:8页:535-539
收录类别SCI
文章类型Article
WOS标题词Science & Technology
类目[WOS]Biophysics ; Oncology ; Hematology ; Immunology ; Transplantation
研究领域[WOS]Biophysics ; Oncology ; Hematology ; Immunology ; Transplantation
关键词[WOS]GRAFT-VERSUS-HOST ; STEM-CELL TRANSPLANTATION ; DONOR LYMPHOCYTE INFUSION ; REGULATORY T-CELLS ; ADOPTIVE IMMUNOTHERAPY ; LEUKEMIA RELAPSE ; DISEASE ; TOLERANCE ; IL-2 ; EXPRESSION
英文摘要

The objective of this study was to determine the efficacy and safety of low-dose recombinant interleukin-2(IL-2) administered to patients with acute lymphoblastic malignancy at high-risk of relapse after unmanipulated HLA-identical or HLA-haploidentical allogeneic hematopoietic stem cell transplantation (allo-HSCT). We studied 19 patients with acute lymphoblastic malignancy who underwent IL-2 treatment for a high probability of disease recurrence after allo-HSCT between July 2004 and June 2006 at Peking University Institute of Hematology. With a median follow-up of 6 months (range, 3-19 months) after the first IL-2 therapy, 14 of 15 evaluable patients in our cohort were disease-free (93.33%), whereas one patient in ′high risk′ pretransplantation category relapsed. Toxicities from IL-2 were mainly fever, pain, redness and swelling at the injection site. Four patients left the study because of hyperpyrexia. Local and reversible chronic GVHD was observed in 6 of 15 patients (40%). Similar cGVHD occurrences were observed between the two groups of patients undergoing HLA-identical HSCT (three of seven patients) and HLA-haploidentical HSCT (two of six patients), respectively. In conclusion, low-dose IL-2 subcutaneous administration from 100 days for a prolonged period could be a safe and effective strategy to prevent relapse in acute lymphoblastic malignancy patients with high risk of recurrence after unmanipulated allo-HSCT.

语种英语
WOS记录号WOS:000260501300006
项目编号2006AA02Z4A0 ; IRT0702
资助机构High Technology Research and Development Program of China ; Key Project Foundation ; Ministry of Public Health and Program for Innovative Research Team in University
引用统计
被引频次:13[WOS]   [WOS记录]     [WOS相关记录]
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/51752
专题北京大学第二临床医学院_血液科
作者单位Peking Univ, Peoples Hosp, Inst Hematol, Beijing 100044, Peoples R China
推荐引用方式
GB/T 7714
Liu, K-Y,Chen, Y-H,Liu, D-H,et al. A pilot study of low-dose recombinant interleukin-2 for acute lymphoblastic malignancy after unmanipulated allogeneic blood and marrow transplantation[J]. BONE MARROW TRANSPLANTATION,2008,42(8):535-539.
APA Liu, K-Y,Chen, Y-H,Liu, D-H,Xu, L-P,&Huang, X-J.(2008).A pilot study of low-dose recombinant interleukin-2 for acute lymphoblastic malignancy after unmanipulated allogeneic blood and marrow transplantation.BONE MARROW TRANSPLANTATION,42(8),535-539.
MLA Liu, K-Y,et al."A pilot study of low-dose recombinant interleukin-2 for acute lymphoblastic malignancy after unmanipulated allogeneic blood and marrow transplantation".BONE MARROW TRANSPLANTATION 42.8(2008):535-539.
条目包含的文件
条目无相关文件。
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Liu, K-Y]的文章
[Chen, Y-H]的文章
[Liu, D-H]的文章
百度学术
百度学术中相似的文章
[Liu, K-Y]的文章
[Chen, Y-H]的文章
[Liu, D-H]的文章
必应学术
必应学术中相似的文章
[Liu, K-Y]的文章
[Chen, Y-H]的文章
[Liu, D-H]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。